Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 14/20 | 0.66 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.66 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 4/20 | 0.50 |
| ▸ | CLK3 | P49761 | 4/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561306 | 0.84 | PIM1 (0.55) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL1560900 | 0.83 | PIM1 (0.57) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL473761 | 0.81 | PIM1 (0.61) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL11929451 | 0.81 | PIM1 (0.58) | PIM1PIM2PIM3CYP2A6CLK2 | |
| SCHEMBL1560941 | 0.79 | PIM1 (0.52) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL473831 | 0.79 | PIM1 (0.52) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL13190544 | 0.78 | PIM1 (0.52) | PIM1PIM2PIM3CYP2A6CLK2 | |
| SCHEMBL1559818 | 0.78 | PIM1 (0.51) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL2218210 | 0.77 | PIM1 (0.51) | PIM1PIM2PIM3CLK2CLK3 | |
| SCHEMBL1561129 | 0.77 | PIM1 (0.51) | PIM1PIM2PIM3CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | PIM1 2969/4885PIM2 3258/4885PIM3 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.